FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4328114910> ?p ?o ?g. }

• W4328114910 abstract "Primary liver cancer is the second leading cause of tumor-related deaths in China, with hepatocellular carcinoma (HCC) accounting for 80%-90% of these. Since there is a lack of symptoms in the early stages of HCC, a large proportion of patients were identified with unresectable HCC when diagnosed. Due to the severe resistance to chemotherapy, patients with advanced HCC were traditionally treated with systematic therapy in the past decades, and the tyrosine kinase inhibitor (TKI) sorafenib has remained the only treatment option for advanced HCC since 2008. Immunotherapies, particularly immune checkpoint inhibitors (ICIs), have shown a strong anti-tumor effect and have been supported by several guidelines recently. ICIs, for example programmed cell death-1 (PD-1) inhibitors such as nivolumab and pembrolizumab, programmed cell death ligand 1 (PD-L1) inhibitors such as atezolizumab, and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibitors such as ipilimumab, the ICI-based combination with TKIs, and VEGF-neutralizing antibody or systematic or local anti-tumor therapies, are being further studied in clinical trials. However, immune-related adverse events (irAEs) including cutaneous toxicity, gastrointestinal toxicity, and hepatotoxicity may lead to the termination of ICI treatment or even threaten patients' lives. This review aims to summarize currently available immunotherapies and introduce the irAEs and their managements in order to provide references for clinical application and further research." @default.
• W4328114910 created "2023-03-22" @default.
• W4328114910 creator A5004933945 @default.
• W4328114910 creator A5030442178 @default.
• W4328114910 creator A5036593983 @default.
• W4328114910 creator A5059867276 @default.
• W4328114910 creator A5089401224 @default.
• W4328114910 date "2023-03-21" @default.
• W4328114910 modified "2023-10-02" @default.
• W4328114910 title "Immunotherapies for advanced hepatocellular carcinoma" @default.
• W4328114910 cites W1914776013 @default.
• W4328114910 cites W1971837077 @default.
• W4328114910 cites W1994993231 @default.
• W4328114910 cites W2010121426 @default.
• W4328114910 cites W2010265466 @default.
• W4328114910 cites W2033577259 @default.
• W4328114910 cites W2052730188 @default.
• W4328114910 cites W2066671159 @default.
• W4328114910 cites W2097995306 @default.
• W4328114910 cites W2101653483 @default.
• W4328114910 cites W2104274330 @default.
• W4328114910 cites W2104696272 @default.
• W4328114910 cites W2119896120 @default.
• W4328114910 cites W2160834915 @default.
• W4328114910 cites W2166662937 @default.
• W4328114910 cites W2312311174 @default.
• W4328114910 cites W2317340981 @default.
• W4328114910 cites W2526282664 @default.
• W4328114910 cites W2560367415 @default.
• W4328114910 cites W2560876009 @default.
• W4328114910 cites W2572174216 @default.
• W4328114910 cites W2606367731 @default.
• W4328114910 cites W2743419024 @default.
• W4328114910 cites W2759997926 @default.
• W4328114910 cites W2760410509 @default.
• W4328114910 cites W2767219591 @default.
• W4328114910 cites W2767343890 @default.
• W4328114910 cites W2777677409 @default.
• W4328114910 cites W2786816161 @default.
• W4328114910 cites W2788726176 @default.
• W4328114910 cites W2805592007 @default.
• W4328114910 cites W2807322325 @default.
• W4328114910 cites W2883204623 @default.
• W4328114910 cites W2883615552 @default.
• W4328114910 cites W2891486030 @default.
• W4328114910 cites W2908767342 @default.
• W4328114910 cites W2935887716 @default.
• W4328114910 cites W2940759533 @default.
• W4328114910 cites W2946166987 @default.
• W4328114910 cites W2955472368 @default.
• W4328114910 cites W2958614241 @default.
• W4328114910 cites W2990602950 @default.
• W4328114910 cites W2992211060 @default.
• W4328114910 cites W2998900184 @default.
• W4328114910 cites W3008952136 @default.
• W4328114910 cites W3014988310 @default.
• W4328114910 cites W3025022288 @default.
• W4328114910 cites W3026099517 @default.
• W4328114910 cites W3045387409 @default.
• W4328114910 cites W3048739245 @default.
• W4328114910 cites W3090413519 @default.
• W4328114910 cites W3091399767 @default.
• W4328114910 cites W3128646645 @default.
• W4328114910 cites W3136958029 @default.
• W4328114910 cites W3152534107 @default.
• W4328114910 cites W3154956818 @default.
• W4328114910 cites W3177988238 @default.
• W4328114910 cites W3182054210 @default.
• W4328114910 cites W3189379297 @default.
• W4328114910 cites W3195864634 @default.
• W4328114910 cites W3196593048 @default.
• W4328114910 cites W3200531414 @default.
• W4328114910 cites W3217566011 @default.
• W4328114910 cites W4200158019 @default.
• W4328114910 cites W4206973935 @default.
• W4328114910 cites W4210774372 @default.
• W4328114910 cites W4232620598 @default.
• W4328114910 cites W4283812631 @default.
• W4328114910 cites W4288045255 @default.
• W4328114910 doi "https://doi.org/10.3389/fphar.2023.1138493" @default.
• W4328114910 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37025485" @default.
• W4328114910 hasPublicationYear "2023" @default.
• W4328114910 type Work @default.
• W4328114910 citedByCount "3" @default.
• W4328114910 countsByYear W43281149102023 @default.
• W4328114910 crossrefType "journal-article" @default.
• W4328114910 hasAuthorship W4328114910A5004933945 @default.
• W4328114910 hasAuthorship W4328114910A5030442178 @default.
• W4328114910 hasAuthorship W4328114910A5036593983 @default.
• W4328114910 hasAuthorship W4328114910A5059867276 @default.
• W4328114910 hasAuthorship W4328114910A5089401224 @default.
• W4328114910 hasBestOaLocation W43281149101 @default.
• W4328114910 hasConcept C121608353 @default.
• W4328114910 hasConcept C126322002 @default.
• W4328114910 hasConcept C143998085 @default.
• W4328114910 hasConcept C197934379 @default.
• W4328114910 hasConcept C2775949291 @default.
• W4328114910 hasConcept C2777701055 @default.
• W4328114910 hasConcept C2778019345 @default.
• W4328114910 hasConcept C2778695046 @default.

• next